BTK and Miyoshi myopathy: We evaluated BTK inhibition with KS151 in combination with some chemotherapeutic agents, such as bortezomib, lenalidomide and panobinostat as a therapeutic strategy for chemo resistant MM stem cell-like cells (CD138−).